A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

Opioid-induced Constipation (OIC) Clinical Trial

Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Clinical Activity of TD-1211 in Subjects With Opioid-Induced Constipation

Status Completed

Clinical Trial Summary

A dose-escalation study to assess the safety, tolerability and clinical activity of TD-1211 in patients with opioid-induced constipation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Constipation
Opioid-induced Constipation (OIC)

Clinical Trial Details

NCT number	NCT01333540
Study type	Interventional
Source	Theravance Biopharma
Contact
Status	Completed
Phase	Phase 2
Start date	May 2011
Completion date	June 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01323790` - Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation	Phase 3
Completed	`NCT01309841` - Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation	Phase 3
Completed	`NCT01395524` - A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation	Phase 3
Recruiting	`NCT05588323` - Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids	Phase 1/Phase 2
Completed	`NCT01336205` - Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation	Phase 3